Home > Oncology > WCLC 2019 > Screening, Detection, and Diagnosis > Tumour mutation score is a better predictor than TMB

Tumour mutation score is a better predictor than TMB

Conference
WCLC 2019
Tumour mutation burden (TMB) is –after programmed death ligand 1 (PD-L1) expression– an intensively investigated biomarker for immune checkpoint inhibitors in patients with non-small-cell lung cancer (NSCLC). However, its efficiency is attenuated by mutations such as epidermal growth factor (EGFR), and testing still is not fully standardised and comparable. Li et al. developed a tumour mutation score (TMS) as a better biomarker to predict response to immune checkpoint inhibitors in patients with established NSCLC. The development was done by defining TMS as the number of genes with nonsynonymous somatic mutations (TMS18 was TMS of 18 favourable genes, integer from 0 to 18). Mutations were detected by targeted next-generation sequencing in 240 NSCLC patients treated with anti-PD-(L)1 monotherapy or in combination with anti-CTLA4 treatment. Durable clinical benefit was defined as progression-free survival (PFS) ≥6 months. TMS, TMB, and PD-L1 expression were ...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on